Merck & Co., Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Davis
- Full Time Employees
- 74,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 126 East Lincoln Avenue Rahway NJ United States of America 07065
- IPO Date
- Jan 13, 1978
- CIK
- 0000310158
- Website
- merck.com
- Similar Companies
- Business
- Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a leading research-intensive biopharmaceutical company that discovers, develops, manufactures, and markets prescription medicines, vaccines, biologic therapies, and animal health products worldwide; key human health offerings include oncology drugs such as Keytruda (pembrolizumab), the PD-1 inhibitor generating $29.5 billion in 2024 revenues for various cancers, Lynparza (olaparib), a PARP inhibitor for BRCA-mutated ovarian cancer, vaccines like Gardasil (HPV vaccine, $8.6 billion in 2024 revenues), ProQuad/M-M-R II/Varivax (MMRV combination vaccine, $2.5 billion in 2024 revenues), and additional products including Cancidas (caspofungin acetate) antifungal, Januvia/Janumet for diabetes, and veterinary pharmaceuticals, vaccines, and health management solutions for livestock and companion animals. Headquartered in Rahway, New Jersey, and founded over 130 years ago, the company operates globally across human health and animal health segments, targeting patients, healthcare providers, and animal health customers in major markets including the United States, Europe, Asia, and emerging regions. Recent developments include a November 2025 research and development funding agreement with Blackstone Life Sciences for $700 million to advance sacituzumab tirumotecan (sac-TMT), an investigational TROP2-targeted antibody-drug conjugate in 15 Phase 3 trials for breast, endometrial, and lung cancers; multiyear manufacturing expansions totaling nearly $6 billion across North Carolina, Delaware, Kansas, and Virginia to boost vaccine, biologic, and Keytruda production capacity as part of a broader $70 billion U.S. investment commitment; and a launched $3 billion restructuring plan emphasizing productivity savings and U.S.-based R&D and manufacturing enhancements.
Company News
Why Is Merck (MRK) Up 18.2% Since Last Earnings Report?
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Why Moderna's Cancer Vaccine Matters to Investors
Merck to Participate in the Wells Fargo 21st Annual Healthcare Conference
Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Warren Buffett Thinks Investors Are "Gambling" Right Now. Here are 2 Stocks That Should Be Safe Bets.
Success after a century of failures: Inside Moderna and Merck's cancer vaccine breakthrough
Merck Stock Hits New 52-Week High: What's Driving the Rally?
Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus
Beverly Hills Private Wealth LLC Cuts Stock Holdings in Merck & Co., Inc. $MRK
Merck & Co., Inc. $MRK Shares Acquired by BlackRock Inc.
Merck Just Gained 19% in a Month. What Would It Take to Get MRK Stock Up to $200?
3 Dividend Stocks to Hold for the Next 10 Years
Explainer: How the Merck/Moderna cancer vaccine works and possible barriers to wide use
What Happens if Moderna's Cancer Vaccine Works
“Give Me Anything But Tech”: Jim Cramer's Bold Call on the Market's Next Big Rotation
Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here's Who's Best Positioned.
Bank of New York Mellon Corp Sells 373,190 Shares of Merck & Co., Inc. $MRK
Bellars Harris Wealth Management LLC Makes New $10.26 Million Investment in Merck & Co., Inc. $MRK